IOBT — IO Biotech, Inc.
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: DK
- Exchange: NASDAQ
- Employees: 80
- Website: https://www.iobiotech.com
Latest SEC filings for IOBT
- SCHEDULE 13G/A — 2026-04-06
- 8-K — 2026-03-31
- 8-K — 2026-02-13
- 8-K — 2026-01-30
- 8-K — 2026-01-21
- 8-K — 2025-12-19
- 8-K — 2025-11-21
- 8-K — 2025-11-18
- 8-K — 2025-11-14
- 10-Q — 2025-11-14
Educational tool only — not investment advice.